Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Sunitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, is a standard of care for first-line treatment of advanced renal-cell carcinoma. In a large, randomized, phase 3 trial involving previously untreated patients, the median progression-free survival with sunitinib was…

http://ift.tt/2FT0uWF